ReviewDrugs2010
Diagnosis, management and prevention of ventilator-associated pneumonia: an update.
Review in Drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Clinical Benefits From Administering Probiotics to Mechanical Ventilated Patients in Intensive Care Unit: A PRISMA-Guided Meta-Analysis.Frontiers in nutrition · 2021Pooled it
- Trial
- Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration.Intensive care medicine · 2015Trial
- Preventing Ventilator-Associated Pneumonia: A Multicenter Cross-Sectional Study of Knowledge, Attitudes, and Practices of Medical Staff in Chinese Hospitals.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Hybrid Cell Membrane-Engineered Nanocarrier for Triple-Action Strategy to Address Pseudomonas aeruginosa Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Evaluating antibiotic therapy for ventilator-associated pneumonia caused by gram-negative bacilli.Surgery open science · 2023Article
- The Biofire® Filmarray® Pneumonia Plus panel for management of lower respiratory tract infection in mechanically-ventilated patients in the COVID-19 era: a diagnostic and cost-benefit evaluation.Diagnostic microbiology and infectious disease · 2023Article
- Construction and Validation of a Predictive Model for the Risk of Ventilator-Associated Pneumonia in Elderly ICU Patients.Canadian respiratory journal · 2023Article
- Differential Gene Sets Profiling in Gram-Negative and Gram-Positive Sepsis.Frontiers in cellular and infection microbiology · 2022Article
- The effect of ventilator-associated pneumonia on the prognosis of intensive care unit patients within 90 days and 180 days.BMC infectious diseases · 2021Article
- Do probiotics help prevent ventilator-associated pneumonia in critically ill patients? A systematic review with meta-analysis.ERJ open research · 2021Review
- Risk Factors for Mortality Due to Ventilator-Associated Pneumonia in a Chinese Hospital: A Retrospective Study.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Differences in microbial etiology between hospital-acquired pneumonia and ventilator-associated pneumonia: a single-center retrospective study in Guang Zhou.Infection and drug resistance · 2019Article
- Ventilator associated pneumonia following liver transplantation: Etiology, risk factors and outcome.World journal of transplantation · 2016Article
- Alveolar pentraxin 3 as an early marker of microbiologically confirmed pneumonia: a threshold-finding prospective observational study.Critical care (London, England) · 2014Observational
- Inducible protein-10, a potential driver of neurally controlled interleukin-10 and morbidity in human blunt trauma.Critical care medicine · 2014Article
- Review
- Gram-negative and Gram-positive bacterial infections give rise to a different metabolic response in a mouse model.Journal of proteome research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ventilator-associated pneumonia (VAP) affects 10-20% of mechanically ventilated patients and is associated with increased morbidity and mortality and high costs. Early diagnosis is crucial for rapid appropriate antimicrobial therapy to be instituted, but debate remains as to the optimal diagnostic strategy. Noninvasive clinical-based diagnosis is rapid but may not be as accurate as invasive techniques. Increased use of biomarkers and advances in genomics and proteomics may help speed up diagnosis. Management of VAP relies principally on appropriate antimicrobial therapy, which should be selected according to individual patient factors, such as previous antibacterial therapy and length of hospitalization or mechanical ventilation, and local infection and resistance patterns. In addition, once bacterial culture and sensitivity results are available, broad-spectrum therapy should be de-escalated to provide a more specific, narrower-spectrum cover. Optimum duration of antibacterial therapy is difficult to define and should be tailored to clinical response. Biomarker levels may be useful to monitor response to therapy. With the high morbidity and mortality, prevention of VAP is important and several strategies have been shown to reduce the rates of VAP in mechanically ventilated patients, including using noninvasive ventilation where possible, and semi-recumbent positioning. Other potentially beneficial preventive techniques include subglottal suctioning, oral decontamination strategies and antimicrobial-coated endotracheal tubes, although further study is needed to confirm the cost effectiveness of these strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.